Skip to main content

Table 1 Characteristics and outcomes of study population by severity of LV dysfunction

From: Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

  Moderate-severe (n = 15) Mild (n = 27) Minimal (n = 72) P value
Clinical characteristics
 Age 55.7 ± 12.4 59.0 ± 9.6 55.9 ± 10.6 0.39
 Post-menopausal 9 (60%) 22 (81%) 50 (69%) 0.40
 Hypertension 4 (27%) 10 (37%) 25 (35%) 0.79
 Diabetes 1 (7%) 2 (7%) 12 (17%) 0.42
 Hyperlipidemia 1 (7%) 3 (11%) 9 (13%) 1.00
 Cigarette smoking (current) 2 (13%) 8 (30%) 10 (14%) 0.19
 Congestive heart failure 0 0 1 (1%) 1.00
 Valve disease 0 0 1 (1%) 1.00
 Arrhythmia 0 0 2 (3%) 1.00
 Coronary artery disease 0 1 (4%) 1 (1%) 0.60
 Stroke 0 0 0 N/A
 HF symptoms with LVEF decline 8 (53%) 4(15%) 15 (21%) 0.01
Cancer characteristics  
 Left-sided cancer 9 (60%) 14 (52%) 39 (54%) 0.10
 Lymph node involvement 7 (47%) 14 (52%) 37 (51%) 0.94
Treatment characteristics  
 Mastectomy 11 (73%) 24 (89%) 61 (85%) 0.42
 Radiation 13 (87%) 21 (78%) 53 (74%) 0.55
  Radiation dose (Gy) 55 (42.5,90) 80 (40,98.4) 53.75 (0,87.25) 0.45
 Anthracycline 15 (100%) 25 (93%) 61 (85%) 0.23
  Cumulative dose (mg/m2) 240 (240,240) 240 (150,240) 240 (150,240) 0.04
 Trastuzumab cycles received 7 (4,11) 14 (10,17) 16 (10,17) 0.002
 Trastuzumab interruption 15 (100%) 27 (100%) 67 (93%) 0.10
 Trastuzumab re-started 6 (40%) 16 (59%) 43 (60%) 0.36
 Completed planned trastuzumab 1 (7%) 10 (37%) 35 (49%) 0.01
Other management
 Cardiology referral 14 (93%) 21 (78%) 40 (56%) 0.006
 Beta blocker 15 (100%) 14 (52%) 28 (39%) < 0.0001
 ACE inhibitor 15 (100%) 18 (67%) 38 (53%) 0.002
 Loop diuretic 9 (60%) 7 (26%) 8 (11%) 0.0001
 Mineralocorticoid receptor antagonist 9 (60%) 1 (4%) 1 (1%) < 0.0001
Outcomes
 Breast cancer recurrence 3 (20%) 5 (19%) 12 (17%) 0.88
 All cause mortality 1 (7%) 4 (15%) 6 (8%) 0.64
  1. Values shown are counts (percentages), mean ± SD, or median (Q1,Q3). Abbreviations: ACE Angiotensin converting enzyme, HF Heart failure, LVEF Left ventricular ejection fraction